Actively Recruiting
Study of Bronchoalveolar Lavage Fluid Biomarkers to Predict Outcomes in Soft Tissue Sarcoma Patients Using Routine Bronchoscopy and Lung Metastasectomy
Led by University Health Network, Toronto · Updated on 2026-03-04
70
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase II, single-center study to investigate biomarkers found in bronchoalveolar lavage fluid BALF and transbronchial aspirate TA in patients with soft tissue sarcoma STS. The goal is to assess these biomarkers in relation to the amount of metastatic disease present. Samples will be collected during routine bronchoscopy procedures performed as part of standard care at Toronto General Hospital, along with tissue samples from lung metastases and nearby normal lung tissue. During the study, BALF and TA samples will be gathered during routine bronchoscopy, and lung metastases tissue along with adjacent normal lung tissue will be collected during standard care metastasectomy surgery. These samples will be analyzed to identify and quantify inflammatory biomarkers related to neutrophil extracellular traps NETs and to understand how these markers correlate with metastatic spread. Participants will undergo bronchoscopy and metastasectomy as part of their usual care, during which samples will be collected. Researchers will measure NET-related inflammatory biomarkers using BALF and TA diagnostic tools over two years. The study will evaluate the relationship between these biomarkers and metastatic burden, with ongoing analysis during this period. The total duration for assessing outcomes is two years, with no specific mention of additional follow-up beyond this timeframe.
CONDITIONS
Brief Title
BAL Fluid Biomarkers in Sarcoma
Research Team
D
David Shultz
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here